Idera Pharmaceuticals, Inc. - Product Pipeline Review - 2015

Published: May, 2015 | Pages: 44 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Idera Pharmaceuticals, Inc. - Product Pipeline Review - 2015

Summary

Global Markets Direct's, 'Idera Pharmaceuticals, Inc. - Product Pipeline Review - 2015', provides an overview of the Idera Pharmaceuticals, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Idera Pharmaceuticals, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Idera Pharmaceuticals, Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Idera Pharmaceuticals, Inc.'s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Idera Pharmaceuticals, Inc.'s pipeline products

Reason to Buy

- Evaluate Idera Pharmaceuticals, Inc.'s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Idera Pharmaceuticals, Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Idera Pharmaceuticals, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Idera Pharmaceuticals, Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Idera Pharmaceuticals, Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Explore the dormant and discontinued projects of Idera Pharmaceuticals, Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

 Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Idera Pharmaceuticals, Inc. Snapshot 5
Idera Pharmaceuticals, Inc. Overview 5
Key Information 5
Key Facts 5
Idera Pharmaceuticals, Inc. - Research and Development Overview 6
Key Therapeutic Areas 6
Idera Pharmaceuticals, Inc. - Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products - Monotherapy 9
Pipeline Products - Out-Licensed Products 10
Out-Licensed Products/Combination Treatment Modalities 11
Idera Pharmaceuticals, Inc. - Pipeline Products Glance 12
Idera Pharmaceuticals, Inc. - Clinical Stage Pipeline Products 12
Phase II Products/Combination Treatment Modalities 12
Phase I Products/Combination Treatment Modalities 13
Idera Pharmaceuticals, Inc. - Early Stage Pipeline Products 14
Preclinical Products/Combination Treatment Modalities 14
Idera Pharmaceuticals, Inc. - Drug Profiles 15
IMO-8400 15
Product Description 15
Mechanism of Action 15
R&D Progress 15
IMO-9200 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
Antisense Oligonucleotide to Inhibit miR-21 for Colon Carcinoma 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
Antisense Oligonucleotides for Genetic Disorder and Cardiovascular Diseases 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
IMO-2055 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
IMO-2125 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
IMO-4200 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
Oligonucleotides to Agonize TLR3 for Infectious Disease and Immunology 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
Idera Pharmaceuticals, Inc. - Pipeline Analysis 26
Idera Pharmaceuticals, Inc. - Pipeline Products by Target 26
Idera Pharmaceuticals, Inc. - Pipeline Products by Route of Administration 27
Idera Pharmaceuticals, Inc. - Pipeline Products by Molecule Type 28
Idera Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action 29
Idera Pharmaceuticals, Inc. - Recent Pipeline Updates 30
Idera Pharmaceuticals, Inc. - Dormant Projects 36
Idera Pharmaceuticals, Inc. - Discontinued Pipeline Products 37
Discontinued Pipeline Product Profiles 37
IMO-2055 37
IMO-2125 37
Idera Pharmaceuticals, Inc. - Company Statement 38
Idera Pharmaceuticals, Inc. - Locations And Subsidiaries 42
Head Office 42
Appendix 43
Methodology 43
Coverage 43
Secondary Research 43
Primary Research 43
Expert Panel Validation 43
Contact Us 43
Disclaimer 44

List of Tables

Idera Pharmaceuticals, Inc., Key Information 5
Idera Pharmaceuticals, Inc., Key Facts 5
Idera Pharmaceuticals, Inc. - Pipeline by Indication, 2015 7
Idera Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2015 8
Idera Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2015 9
Idera Pharmaceuticals, Inc. - Out-Licensed Products in Pipeline, 2015 10
Idera Pharmaceuticals, Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2015 11
Idera Pharmaceuticals, Inc. - Phase II, 2015 12
Idera Pharmaceuticals, Inc. - Phase I, 2015 13
Idera Pharmaceuticals, Inc. - Preclinical, 2015 14
Idera Pharmaceuticals, Inc. - Pipeline by Target, 2015 26
Idera Pharmaceuticals, Inc. - Pipeline by Route of Administration, 2015 27
Idera Pharmaceuticals, Inc. - Pipeline by Molecule Type, 2015 28
Idera Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action, 2015 29
Idera Pharmaceuticals, Inc. - Recent Pipeline Updates, 2015 30
Idera Pharmaceuticals, Inc. - Dormant Developmental Projects,2015 36
Idera Pharmaceuticals, Inc. - Discontinued Pipeline Products, 2015 37